AZD1222 claims 79% effecacy in pivotal US study
Following assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1177 entries already.
Entries by Thomas Gabrielczyk
EMA recommends to continue AZD1222 vaccinations
/in News/by Thomas GabrielczykOn Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Novel COVID antibody enters clinical testing
/in News/by Thomas GabrielczykGerman CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days.
B.1.1.7 variant associated with higher mortality
/in News/by Thomas GabrielczykThe B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Roche in take-over deal with GenMark Diagnostics
/in News/by Thomas GabrielczykRoche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.
Media hype on Denmarks decision to halt AZD1222 vaccination
/in News/by Thomas GabrielczykWhile media reports suggest AstraZenecas COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship.
Roche Phase III study misses COVID-19 endpoint
/in News/by Thomas GabrielczykSwiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia.
BioPhero A/S raises US$17m in Series A funding
/in News/by Thomas GabrielczykDanish sustainable crop protection company, BioPhero AS, has raised $17m in Series A funding led by DCVC Bio.
PCR-test reveals risk of genotoxity of genome editing
/in News/by Thomas GabrielczykGerman researchers have presented a new method to assess on-target and off-target effects of CRISPR-Cas nucleases or TALENs.
EMA starts rolling review for Sputnik V vaccine
/in News/by Thomas GabrielczykEMAs human medicines committee has started a rolling review of Sputnik V, a COVID-19 vaccine developed by Russias Gamaleya National Centre of Epidemiology and Microbiology.